Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 3 results out of 3
Data Insights
LY-3972406 by Eli Lilly and Co for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
LY-3972406 is under clinical development by Eli Lilly and Co and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris)....
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's LY-3972406?
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis...
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's LY-3972406?
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis...